Expect a dilutive equity offering shortly after the August 14 EGM if the proposal passes. Monitor for subsequent S-1 or prospectus filings. The massive authorized share increase signals imminent capital raise that will likely pressure the stock price.
Price Chart
Executive Summary
Virax Biolabs is seeking shareholder approval to increase authorized share capital from 2 million to 500 million ordinary shares (a 250x increase), enabling massive future equity dilution. The extraordinary general meeting is set for August 14, 2026, with the board unanimously recommending approval to fund operations and clinical development of ViraxImmune.
Key Facts
- Authorized share capital to increase from US$50,000 (2M shares) to US$12,500,000 (500M shares) — a 498M share increase
- Extraordinary General Meeting scheduled for August 14, 2026; record date July 27, 2026
- Board unanimously recommends voting FOR the share capital increase and charter amendment
- Company explicitly states the increase is for 'basic financing needs' and 'clinical and regulatory development of ViraxImmune'
- Current market capitalization is approximately $2M, making the authorized share increase 250x the current authorized base
Financial Impact
Potential for extreme dilution: authorized shares would increase 250x from 2M to 500M, enabling the company to issue equity worth many multiples of its current $2M market cap
Risk Factors
- Extreme shareholder dilution from future equity issuances
- Stock price decline as market prices in dilution risk
- Potential for distressed financing terms given micro-cap status and urgent funding needs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-326851 |
| Document: vrax-ex99_1.htm | 0001193125-26-326851 |
| Document: 6-k_special_meeting_auth.htm | 0001193125-26-326851 |
| Document: 0001193125-26-326851-index-headers.html | 0001193125-26-326851 |
| Document: 0001193125-26-326851-index.html | 0001193125-26-326851 |
| Document: 0001193125-26-326851.txt | 0001193125-26-326851 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 16d ago | 6-K | $1.85 | awaiting T+20 | — | $1.18 (−36.22%) |
Sep 4, 2026 7w ago | 6-K | $2.63 $2.03 | ▲ +22.81% | ▲ +24.53% | $1.18 (+55.13%) |
Sep 4, 2026 7w ago | EFFECT | $2.63 $2.40 | ▼ −8.57% | ▼ −9.17% | $1.18 (−55.05%) |
Aug 18, 2026 9w ago | 6-K | $2.76 $2.45 | ▼ −11.20% | ▼ −10.21% | $1.18 (−57.25%) |
Jul 31, 2026 12w ago | 6-K | $2.62 $2.82 | ▼ −7.63% | ▼ −4.65% | $1.18 (+54.96%) |
Jul 16, 2026 14w ago | 6-K | $3.90 $2.82 | ▼ −27.69% | ▼ −31.31% | $1.18 (−69.74%) |
Jul 9, 2026 15w ago | Press Release | $6.36 $2.77 | ▲ +56.45% | ▲ +58.69% | $1.18 (+81.45%) |
Jul 9, 2026 15w ago | 6-K | $6.36 $2.77 | ▼ −56.45% | ▼ −58.69% | $1.18 (−81.45%) |
Jun 24, 2026 17w ago | 6-K | $0.1350 $0.1276 | ▼ −5.48% | ▼ −6.11% | $1.18 (+774.07%) |
Jun 12, 2026 19w ago | 6-K | $0.1840 $0.1496 | ▼ −18.70% | ▼ −20.05% | $1.18 (+541.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers